Clinical trial

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Ofatumumab Normalized identity: ofatumumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention First line DMT Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-07-23

PhasePHASE3

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

OfatumumabDRUG · verified · RxNorm: ofatumumab

First line DMTDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

MadridSpain3 BerlinGermany2 BarcelonaSpain1 ValenciaSpain1 SevilleSpain1 MontpellierFrance1 StrasbourgFrance1 BordeauxFrance1 NaplesItaly1 MálagaSpain1 RennesFrance1 NiceFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04788615 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.